Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Starna Therapeutics Closes $40M Series B+ Round to Advance In Vivo CAR-T and Extrahepatic mRNA Delivery Platforms

Fineline Cube May 11, 2026
Company Deals

CureGene Pharmaceutical Secures RMB 300 Million Series C to Advance Global Clinical Pipeline

Fineline Cube May 9, 2026
Company Deals

Hengrui Pharmaceuticals Expands Greater Bay Area Presence with Hong Kong Office Launch and Cancer Foundation Partnership

Fineline Cube May 9, 2026
Company Deals

Fosun Pharma Secures Exclusive China Rights to InxMed’s FAK Inhibitors for Solid Tumor Treatment

Fineline Cube May 9, 2026
Company Deals

Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies

Fineline Cube May 8, 2026
Policy / Regulatory

NHSA Launches 2026 NRDL Adjustment with Expanded Eligibility Criteria and Revised Weight Standards

Fineline Cube May 11, 2026
Company Drug

Henlius Biotech Expands European Footprint with Two Additional EC Approvals for HanSiZhuang PD-1 Inhibitor

Fineline Cube May 11, 2026
Company Drug

Henlius Biotech Receives FDA Clearance for Phase I Trial of HLX05-N Cetuximab Biosimilar in Metastatic Colorectal Cancer

Fineline Cube May 11, 2026
Company

Jiuzhou Pharmaceutical Shuts Down Two Subsidiaries to Streamline Operations

Fineline Cube Jun 20, 2024

Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHA: 603456), a pharmaceutical company based in China, has announced...

Company Drug

Keymed Biosciences’ CM313 Shows Promise in Treating Immune Thrombocytopenia, NEJM Study Says

Fineline Cube Jun 20, 2024

Keymed Biosciences Inc. (HKG: 2162), a biopharmaceutical company based in China, has published results from...

Company Deals

Xencor Reclaims Rights to Plamotamab After Janssen Halts Development

Fineline Cube Jun 20, 2024

Xencor Inc. (NASDAQ: XNCR), a U.S.-based biotechnology company, has announced that Johnson & Johnson (J&J,...

Company Drug

AbbVie’s Skyrizi Secures FDA Approval for Ulcerative Colitis, Expands Treatment Portfolio

Fineline Cube Jun 20, 2024

AbbVie (NYSE: ABBV) has announced that the U.S. Food and Drug Administration (FDA) has approved...

Company Deals

Genrix Biopharmaceutical and Chongqing Pharmaceutical Group Form Strategic Partnership to Boost Market Launch

Fineline Cube Jun 20, 2024

Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443), a biopharmaceutical company based in China, has entered...

Company

AstraZeneca’s Gracell Biotechnologies to Expand Cell Therapy Manufacturing in China

Fineline Cube Jun 20, 2024

Gracell Biotechnologies, a China-based cell therapy specialist owned by AstraZeneca (AZ; NASDAQ: AZN), is reportedly...

Company Drug

NMPA Releases 81st Batch of Reference Drugs for Generic Quality Consistency Evaluation

Fineline Cube Jun 19, 2024

The National Medical Products Administration (NMPA) has released the 81st batch of reference drugs for...

Company Deals

Grifols Completes Sale of 20% Stake in Shanghai RAAS to Haier Group for RMB 12.5 Billion

Fineline Cube Jun 19, 2024

Grifols AS (NASDAQ: GRFS), a Spain-based global leader in the production of blood products, has...

Company Deals

3SBio Secures Long-Term Financing from IFC for Manufacturing and Global Expansion

Fineline Cube Jun 19, 2024

3SBio Inc. (HKG: 1530), a biopharmaceutical company based in China, is slated to receive long-term...

Company Medical Device

Hybribio Ltd Secures NMPA Approval for α-Thalassemia Genotyping Detection Kit

Fineline Cube Jun 19, 2024

Hybribio Ltd (SHE: 300639), a Guangdong-based provider of nucleic acid molecular diagnostic products, has announced...

Company Drug

Kanghong Pharmaceutical’s Lumitin Approved in Myanmar for Neovascular AMD Treatment

Fineline Cube Jun 19, 2024

Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773), a Chinese pharmaceutical company, has announced that...

Company Drug

Suzhou Zelgen’s Recombinant Human Thyroid Stimulating Hormone Accepted for NMPA Review

Fineline Cube Jun 19, 2024

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a biopharmaceutical company based in China, has announced...

Company Deals

Sanofi Partners with Belharra Therapeutics to Tap into Chemoproteomics for Immunology Targets

Fineline Cube Jun 19, 2024

Sanofi (NASDAQ: SNY; EPA: SAN), a major French pharmaceutical company, has formed a collaboration with...

Company Drug

Clover Biopharmaceuticals’ RSV Vaccine Candidate Shows Promising Results in Elderly

Fineline Cube Jun 19, 2024

Clover Biopharmaceuticals Ltd. (HKG: 2197), a biopharmaceutical company based in China, has announced positive preliminary...

Company Deals

Day One Biopharmaceuticals Expands Pipeline with MabCare Therapeutics Licensing Deal

Fineline Cube Jun 19, 2024

Day One Biopharmaceuticals (NASDAQ: DAWN), a California-based biotech company that recently celebrated its first drug...

Company Drug

China Medical System’s Methylthioninium Tablets Get NMPA Green Light for Colonoscopy Use

Fineline Cube Jun 19, 2024

China Medical System Holdings (CMS; HKG: 0867) has announced that it has received New Drug...

Company Drug

AstraZeneca’s AKT Inhibitor Truqap Misses Primary Endpoints in Phase III TNBC Trial

Fineline Cube Jun 19, 2024

AstraZeneca (NASDAQ: AZN), a leading UK-based pharmaceutical company, has encountered a setback in the Phase...

Company Drug

MSD’s Capvaxive Vaccine Targets 21 Serotypes of Streptococcus Pneumoniae

Fineline Cube Jun 19, 2024

Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK), a leading U.S. pharmaceutical company, has announced...

Company Deals

Roche Secures RNA Exon Editing Tech for Neurological Diseases with Ascidian Deal

Fineline Cube Jun 19, 2024

Roche (SWX: ROG; OTCMKTS: RHHBY), a Swiss pharmaceutical giant, is expanding its footprint in the...

Policy / Regulatory

Gansu Province Introduces Measures for Management of Pharmaceutical Personnel

Fineline Cube Jun 18, 2024

The Gansu Medical Products Administration has issued a set of “Measures for the Management of...

Posts pagination

1 … 340 341 342 … 663

Recent updates

  • GSK Partners with Sino Biopharmaceutical’s CTTQ Subsidiary to Commercialize Bepirovirsen in China’s Hepatitis B Market
  • Starna Therapeutics Closes $40M Series B+ Round to Advance In Vivo CAR-T and Extrahepatic mRNA Delivery Platforms
  • Henlius Biotech Expands European Footprint with Two Additional EC Approvals for HanSiZhuang PD-1 Inhibitor
  • Henlius Biotech Receives FDA Clearance for Phase I Trial of HLX05-N Cetuximab Biosimilar in Metastatic Colorectal Cancer
  • MicroPort CardioFlow Secures CE Mark for ENO Series Pacemakers with Advanced LBBAP Capability
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Others

GSK Partners with Sino Biopharmaceutical’s CTTQ Subsidiary to Commercialize Bepirovirsen in China’s Hepatitis B Market

Company Deals

Starna Therapeutics Closes $40M Series B+ Round to Advance In Vivo CAR-T and Extrahepatic mRNA Delivery Platforms

Company Drug

Henlius Biotech Expands European Footprint with Two Additional EC Approvals for HanSiZhuang PD-1 Inhibitor

Company Drug

Henlius Biotech Receives FDA Clearance for Phase I Trial of HLX05-N Cetuximab Biosimilar in Metastatic Colorectal Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.